H
HoyleCohen Portfolio holdings
AUM
$1.32B
1-Year Est. Return
27.05%
1 Year Est. Return
+27.05%
AUM
$1.31B
AUM Growth
+$87.1M
(+7.1%)
Holding
287
Top Buys
| 1 | +$3.13M | |
| 2 | +$2.96M | |
| 3 | +$1.79M | |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.46M |
| 5 |
Novo Nordisk
NVO
|
+$1.38M |
Top Sells
| 1 | +$5.35M | |
| 2 | +$3.87M | |
| 3 | +$3.48M | |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$1.88M |
| 5 |
SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
|
+$1.45M |
Sector Composition
| 1 | Technology | 24.67% |
| 2 | Financials | 11.09% |
| 3 | Healthcare | 7.57% |
| 4 | Communication Services | 6.46% |
| 5 | Industrials | 5.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Warner Bros
WBD
$45.5B
| $97.6K | 0.01% |
11,182
-783
|
|
||
|
IGR
277
CBRE Global Real Estate Income Fund
IGR
$752M
| $53.8K | ﹤0.01% |
+10,000
|
|
||
278
Standard BioTools
LAB
$500M
| $35.2K | ﹤0.01% |
+13,002
|
|
||
279
Personalis
PSNL
$936M
| $22.9K | ﹤0.01% |
15,373
|
|
||
|
AKTS
280
DELISTED
Akoustis Technologies Inc
AKTS
| $21.6K | ﹤0.01% |
36,502
|
|
||
|
VIRX
281
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $14.3K | ﹤0.01% |
14,000
|
|
||
|
TCON
282
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $5.59K | ﹤0.01% |
650
|
|
||
283
Halozyme
HALO
$7.84B
| – | – |
-8,775
|
|
||
284
Nuveen California Quality Municipal Income Fund
NAC
$1.7B
| – | – |
-12,296
|
|
||
285
Vertex Pharmaceuticals
VRTX
$107B
| – | – |
-528
|
|
||
286
Zscaler
ZS
$48.5B
| – | – |
-906
|
|
||
|
SLGC
287
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| – | – |
-11,714
|
|